Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030004/S043

Apollo Onyx Delivery Micro Catheter

Ev3 Neurovascular · Decision date May 26, 2026

FDA DECISIONP030004/S043

What did the FDA decide?

FDA records P030004/S043 as a supplement to PMA P030004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 26, 2026.

FDA approval order statement

approval of a new supplier for the dispenser coil component and its tubing supplier for the Apollo Onyx Delivery Micro Catheter
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
May 26, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P030004/S043
Regulatory pathway
PMA supplement
Product code
MFE
Decision code
OK30
Decision date
May 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, injectable, embolic.

Product code
MFE
FDA device class
3

For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030004 · Original PMA

    ONYX LIQUID EMBOLIC SYSTEM

  2. P030004/S035 · Related supplement

    Onyx Liquid Embolic System (LES)

  3. P030004/S041 · Related supplement

    Apollo Onyx Delivery Micro Catheter

  4. P030004/S043 received

    Application receipt date recorded by FDA.

  5. P030004/S040 · Related supplement

    Onyx Liquid Embolic System (LES)

  6. P030004/S043 · FDA decision

    30-Day Notice

  7. P030004/S044 · Related supplement

    Onyx Liquid Embolic System

  8. P030004/S042 · Related supplement

    Onyx Liquid Embolic System (LES)

  9. P030004/S039 · Related supplement

    Onyx Liquid Embolic System (Onyx LES)

Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030004

Product / regulatory recordCompanyPathwayDecision dateSource
Ev3 NeurovascularPMA approvalJul 21, 2005FDA
Ev3 NeurovascularPMA supplementDec 8, 2025FDA
Ev3 NeurovascularPMA supplementApr 9, 2026FDA
Ev3 NeurovascularPMA supplementApr 29, 2026FDA
Ev3 NeurovascularPMA supplementJul 21, 2026FDA
Ev3 NeurovascularPMA supplementAug 5, 2026FDA
Ev3 NeurovascularPMA supplementOct 14, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ev3 Neurovascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9775 Toledo Way, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records